Carmustine

Generic Name
Carmustine
Brand Names
Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)
Drug Type
Small Molecule
Chemical Formula
C5H9Cl2N3O2
CAS Number
154-93-8
Unique Ingredient Identifier
U68WG3173Y
Background

A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...

Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Associated Conditions
Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
-
Clinical Trials
Related News

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

First Posted Date
2007-06-04
Last Posted Date
2018-02-14
Lead Sponsor
Stanford University
Target Recruit Count
50
Registration Number
NCT00481832
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

First Posted Date
2007-05-22
Last Posted Date
2017-01-11
Lead Sponsor
Sally Arai
Target Recruit Count
22
Registration Number
NCT00477035
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

First Posted Date
2007-05-11
Last Posted Date
2016-03-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
93
Registration Number
NCT00472056
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

First Posted Date
2007-02-23
Last Posted Date
2019-09-10
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT00439556
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease

First Posted Date
2006-10-16
Last Posted Date
2017-06-14
Lead Sponsor
Stanford University
Target Recruit Count
146
Registration Number
NCT00388349
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

First Posted Date
2006-07-10
Last Posted Date
2017-12-12
Lead Sponsor
Stanford University
Target Recruit Count
102
Registration Number
NCT00349778
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

First Posted Date
2006-07-10
Last Posted Date
2021-09-23
Lead Sponsor
Stanford University
Target Recruit Count
11
Registration Number
NCT00350181
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

First Posted Date
2006-06-29
Last Posted Date
2020-07-14
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
473
Registration Number
NCT00345865
Locations
🇺🇸

Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Not Applicable
Conditions
Lymphoma
First Posted Date
2006-04-24
Last Posted Date
2015-09-25
Lead Sponsor
European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma
Target Recruit Count
96
Registration Number
NCT00317408
Locations
🇨🇿

University Hospital Brno, Brno, Czech Republic

🇧🇪

U.Z. Gasthuisberg, Leuven, Belgium

🇩🇪

Krankenhaus Muenchen Schwabing, Munich, Germany

and more 91 locations

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

First Posted Date
2006-01-25
Last Posted Date
2017-09-27
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
200
Registration Number
NCT00281879
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy